1. Scrip
  3. >>Earnings

2017 Pharma Sales: A New Global Order

 
• By John Hodgson

As the reality of annual results arrive, Scrip predicts how the top of the pharma league table is likely to change.

Podium
Who had the biggest pharma revenue in 2017?

The last week in January and the first week in February are full of surprises. They bring the financial results of all the top 15 pharmaceutical companies (except those of Bayer AG, which arrive at the end of February). The circus started on Jan. 23 with news from Johnson & Johnson that its pharma sales hit $36.3bn, up 8.3% from 2016, over half of the increase being due to its mid-year acquisition of Actelion.

Scrip is interested in drug sales, so other product sales – in animal health, diagnostics, medical technology, for instance – are excluded

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

Sarepta Slammed By Double Blow: Elevidys Sales Miss, Prasad’s CBER Appointment

 
• By Mandy Jackson

Sarepta’s stock price was battered after Vinay Prasad was appointed to lead the US FDA’s CBER, then the company’s shares were bruised when Q1 Elevidys sales came in below consensus.

BeiGene To Trade Beach For Chalet In Swiss Redomiciling As BeOne

 
• By Alaric DeArment

The biotech saw a slight quarter-over-quarter decline in sales from the BTK inhibitor Brukinsa, which it attributed to seasonality, while revenues overall missed some analyst estimates.

Copycats Compound Novo’s Wegovy Growth Problems

 
• By Andrew McConaghie

The US FDA has ordered compounders of the Danish firm's obesity drug semaglutide to shut up shop later this month, but competition from Eli Lilly is only increasing.

Stock Watch: Market Optimism Outshines Q1 Currency And Tariff Woes

 
• By Andy Smith

The weak US dollar helped some companies reporting first-quarter results and hindered others reporting in stronger currencies. But even the impacts of currencies and Medicare modernization on first-quarter revenues were overlooked when an end to the trade wars seemed possible.

More from Business